ReviewTherapeutic advances in neurological disorders2017
Botulinum toxin in the management of chronic migraine: clinical evidence and experience.
Review in Therapeutic advances in neurological disorders, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Extracranial Trigger Site Surgery for Migraine: A Systematic Review With Meta-Analysis on Elimination of Headache Symptoms.Frontiers in neurology · 2019Pooled it
- Article
- Botulinum toxin for chronic migraine.Journal of neural transmission (Vienna, Austria : 1996) · 2026Review
- Geriatric Migraine, Geroscience, and Sustainable Development Goals: Bridging Clinical Complexity and Public Health Priorities.Journal of clinical medicine · 2026Review
- Cholera Toxin-Mediated Targeting of Botulinum Neurotoxin Activity to Pain-Associated Sensory Neurons.Toxins · 2026Article
- The use of triptans and other acute treatments for the management of migraine in routine clinical practice in England: a retrospective cohort study using the Clinical Practice Research Datalink (CPRD).BMC primary care · 2025Article
- Article
- Exploring potential biomarkers and lead molecules in gastric cancer by network biology, drug repurposing and virtual screening strategies.Molecular diversity · 2025Article
- Botulinum Toxin Therapy: A Comprehensive Review on Clinical and Pharmacological Insights.Journal of clinical medicine · 2025Review
- A Systematic Review and Meta-Analysis of Randomized Controlled Trials for Electroacupuncture Treatment of Migraine.Journal of pain research · 2025Review
- Exploring New and Potential Indications for Botulinum Toxin Treatment: An Updated Literature Review.Cureus · 2024Review
- Direct Comparison of Treatment Outcome Between the Botulinum Toxin and Calcitonin Gene-Related Peptide Monoclonal Antibody in Migraine Patients.Journal of clinical medicine research · 2024Article
- Non-Migraine Head Pain and Botulinum Toxin.Toxins · 2024Review
- Article
- Exploring Novel Therapeutic Targets in the Common Pathogenic Factors in Migraine and Neuropathic Pain.International journal of molecular sciences · 2023Review
- Switching OnabotulinumtoxinA to Monoclonal Anti-CGRP Antibodies in Drug-Resistant Chronic Migraine.CNS drugs · 2023Article
- Sensory Symptoms Associated with Aesthetic Botulinum Toxin A Treatments.Plastic and reconstructive surgery. Global open · 2022Article
- Three Dimensions of Association Link Migraine Symptoms and Functional Connectivity.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2022Article
- OnabotulinumtoxinA in chronic migraine: is the response dose dependent?BMC neurology · 2022Article
- A novel technique of botulinum toxin injection around skull sutures for chronic migraine: A randomized controlled clinical trial.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic migraine (CM) is a severely disabling neurological condition characterized by episodes of pulsating unilateral or bilateral headache. The United States Food and Drug Administration (FDA) approved onabotulinumtoxinA (Botox
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.